Tirzepatide
GLP-1 Agonists
$208.00 ~
Mounjaro 2.5mg is the initiation dose of tirzepatide, a groundbreaking dual incretin receptor agonis...
Mounjaro 2.5mg is the initiation dose of tirzepatide, a groundbreaking dual incretin receptor agonist that targets both GLP‑1 and GIP pathways. Designed as a once-weekly subcutaneous injection, it is FDA-approved for the treatment of type 2 diabetes in adults and delivers robust glycemic control by enhancing insulin secretion, suppressing glucagon release, and delaying gastric emptying. The dual receptor targeting enables broader metabolic effects compared to GLP-1 monotherapy. Although significant weight reduction has been observed in clinical studies, Mounjaro is not approved for obesity treatment; its role in weight loss is considered secondary. Notably, emerging research suggests its potential to reduce the risk of progression from prediabetes, improve outcomes in patients with obesity-related obstructive sleep apnea (OSA), and possibly modulate long-term risks associated with metabolic diseases, including certain cancers. The 2.5mg dose is intended strictly for treatment initiation and is not meant for long-term maintenance.
Show more
